肠道微生物及其代谢产物与心力衰竭相关性研究进展  

Research progress on the relationship between intestinal microbes and their metabolites and heart failure

作　　者：郝佳慧 尹德春(综述)[1] 曲秀芬(审校)[1] Hao Jiahui;Yin Dechun;Qu Xiufen(Department of Cardiology,the First Affiliated Hospital of Harbin Medical University, Heilongjiang Province,Harbin 150000, China)

机构地区：[1]哈尔滨医科大学附属第一临床医学院心血管内科,150000

出　　处：《疑难病杂志》2021年第1期90-93,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：中国博士后科学基金面上资助项目(2018M631959);黑龙江省博士后基金资助项目(LBH-Z18213)。

摘　　要：心力衰竭是各种心脏疾病的终末阶段,具有较高的再入院率和病死率。体循环充血、肠壁水肿及肠黏膜屏障功能受损,使细菌移位、代谢产物蓄积而导致机体处于炎性反应状态,加速心力衰竭患者病情进展。肠道微生物群在心力衰竭病理生理中发挥重要的作用,其代谢途径三甲胺/氧化三甲胺、短链脂肪酸、胆酸途径等都与心脏衰竭有着一定的关系,因此肠道微生物可能成为治疗心力衰竭新的靶点。Heart failure is the terminal stage of various heart diseases,with a high readmission rate and fatality rate.Systemic circulatory congestion,intestinal wall edema,and intestinal mucosal barrier function are impaired,causing bacterial translocation and accumulation of metabolites,leading the body to an inflammatory reaction state,and accelerating the progression of heart failure patients.The intestinal microbiota plays an important role in the pathophysiology of heart failure.Its metabolic pathways such as trimethylamine/trimethylamine oxide,short-chain fatty acids,and bile acid pathways are all related to heart failure.Therefore,intestinal microbes may be used to treat heart failure.Deplete new targets.

关 键 词：肠道微生物 微生物代谢 心力衰竭 相关性 

分 类 号：R541.6[医药卫生—心血管疾病]